Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

James F Blake

Showing results (1-10 of 29) with videos related to

Pageof 3
Sort By:
Medicinal Chemistry (Shariqah (United Arab Emirates))|June 22, 2006
Identification and evaluation of molecular properties related to preclinical optimization and clinical fateJames F Blake
Current Opinion in Chemical Biology|August 4, 2004
Integrating cheminformatic analysis in combinatorial chemistryJames F Blake
Biotechniques|June 20, 2003
Examination of the computed molecular properties of compounds selected for clinical developmentJames F Blake
Current Opinion in Drug Discovery & Development|June 26, 2004
Structure-based generation of viable leads from small combinatorial librariesEllen R Laird, James F Blake
Journal of Molecular Graphics & Modelling|February 23, 2002
Consensus scoring for ligand/protein interactionsRobert D Clark, Alexander Strizhev, Joseph M Leonard, et al.
Pharmaceutical Research|March 10, 2018
Use of QSPR Modeling to Characterize In Vitro Binding of Drugs to a Gut-Restricted PolymerChristine Taylor Brew, James F Blake, Anita Mistry, et al.
Bioorganic & Medicinal Chemistry Letters|March 3, 2007
Tetrazole and ester substituted tetrahydoquinoxalines as potent cholesteryl ester transfer protein inhibitorsC Todd Eary, Zachary S Jones, Robert D Groneberg, et al.
Bioorganic & Medicinal Chemistry Letters|December 17, 2008
3-Hydroxyisoquinolines as inhibitors of HCV NS5b RNA-dependent RNA polymeraseRobert T Hendricks, Stacey R Spencer, James F Blake, et al.
Oncology Research|September 23, 2011
Single-agent inhibition of Chk1 is antiproliferative in human cancer cell lines in vitro and inhibits tumor xenograft growth in vivoKurtis D Davies, Michael J Humphries, Francis X Sullivan, et al.
Journal of Medicinal Chemistry|January 20, 2006
Potent and selective mitogen-activated protein kinase kinase (MEK) 1,2 inhibitors. 1. 4-(4-bromo-2-fluorophenylamino)-1- methylpyridin-2(1H)-onesEli M Wallace, Joseph Lyssikatos, James F Blake, et al.
Pageof 3

Showing results (1-10 of 29) with videos related to

Sort By:
Pageof 3
Medicinal Chemistry (Shariqah (United Arab Emirates))|June 22, 2006
Identification and evaluation of molecular properties related to preclinical optimization and clinical fateJames F Blake
Current Opinion in Chemical Biology|August 4, 2004
Integrating cheminformatic analysis in combinatorial chemistryJames F Blake
Biotechniques|June 20, 2003
Examination of the computed molecular properties of compounds selected for clinical developmentJames F Blake
Current Opinion in Drug Discovery & Development|June 26, 2004
Structure-based generation of viable leads from small combinatorial librariesEllen R Laird, James F Blake
Journal of Molecular Graphics & Modelling|February 23, 2002
Consensus scoring for ligand/protein interactionsRobert D Clark, Alexander Strizhev, Joseph M Leonard, et al.
Pharmaceutical Research|March 10, 2018
Use of QSPR Modeling to Characterize In Vitro Binding of Drugs to a Gut-Restricted PolymerChristine Taylor Brew, James F Blake, Anita Mistry, et al.
Bioorganic & Medicinal Chemistry Letters|March 3, 2007
Tetrazole and ester substituted tetrahydoquinoxalines as potent cholesteryl ester transfer protein inhibitorsC Todd Eary, Zachary S Jones, Robert D Groneberg, et al.
Bioorganic & Medicinal Chemistry Letters|December 17, 2008
3-Hydroxyisoquinolines as inhibitors of HCV NS5b RNA-dependent RNA polymeraseRobert T Hendricks, Stacey R Spencer, James F Blake, et al.
Oncology Research|September 23, 2011
Single-agent inhibition of Chk1 is antiproliferative in human cancer cell lines in vitro and inhibits tumor xenograft growth in vivoKurtis D Davies, Michael J Humphries, Francis X Sullivan, et al.
Journal of Medicinal Chemistry|January 20, 2006
Potent and selective mitogen-activated protein kinase kinase (MEK) 1,2 inhibitors. 1. 4-(4-bromo-2-fluorophenylamino)-1- methylpyridin-2(1H)-onesEli M Wallace, Joseph Lyssikatos, James F Blake, et al.
Pageof 3